Spotlight Innovation Inc. Company Profile, Contacts & Intelligence

Spotlight Innovation Inc. Overview

Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. At this time, we are focused on four major platforms: cancer, spinal muscular atrophy (SMA), the Zika virus and chronic pain. Cancer: Spotlight Innovation subsidiary Celtic Biotech Iowa, Inc., is developing novel therapeutic products for the treatment of cancer. Derived from specialized receptor binding proteins found in rattlesnake venom, these product candidates have the potential to reduce treatment costs, increase survival and improve quality-of-life for cancer patients. Spinal Muscular Atrophy: SMA is an autosomal recessive disorder that is a leading genetic cause of death in infants and toddlers and affects between 1 in 6,000 and 1 in 10,000 newborns. An infant who inherits no intact SMN1 gene from either parent may develop SMA and lose the ability to sit, stand, walk, swallow, and/or breathe. In about 60% of cases, patients with SMA die by age two. Spotlight Innovation has obtained an exclusive, worldwide license from Indiana University Research and Technology Corp. to commercialize STL-182, an orally-available small molecule that may have therapeutic potential for treating SMA. Zika virus: Spotlight Innovation has obtained from the Florida State University Research Foundation exclusive, worldwide rights to develop and commercialize certain compounds for the treatment of viral infections, including Zika virus (ZIKV) infection. Chronic Pain: Spotlight Innovation subsidiary Caretta Therapeutics has developed Venodol, a non-opioid, non-addictive over-the-counter treatment for chronic pain due to inflammation. The active ingredient is cobra venom which contains several proteins that exert analgesic activity. Our first product, Venodol Roll-on, is available on Amazon, Walmart.com and Venodol.com. We are currently developing other strengths and formats such as an oral spray.

Headquarters

Urbandale, Ia

Website

spotlightinnovation.com

Industry

Hospitals And Health Care

Founded

2006

NAICS

Health Care and Social Assistance, Social Assistance

Phone Number

Available in AeroLeads

Company Email

Available in AeroLeads

Spotlight Innovation Inc. Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Compare Similar Companies to Spotlight Innovation Inc.

Explore companies in related markets and compare their industry and employee estimates.